04.03.2025 • News

WE Soda Buys Soda Ash Producer Genesis Alkali

WE Soda has acquired Genesis Alkali (Alkali), the largest US-based producer of natural soda ash, from Genesis Energy in an all-cash transaction for $1.425 billion.

According to WE Soda, the acquisition establishes it as the largest global producer of soda ash, increasing the company’s total production capacity to approximately 9.5 million metric tons per year (mtpa).

Alasdair Warren, CEO of WE Soda, commented: "The acquisition of Alkali represents a significant strategic milestone; it provides the foundation for our future growth, strengthens our industry leadership position, enhances our ability to serve our customers globally and gives us the opportunity to unlock significant operational and efficiency benefits for our stakeholders.

“We are now the largest producer of soda ash globally and the only producer that is 100% natural, further underscoring our sustainability leadership. We have diversified our portfolio operationally and geographically and we now have access to infrastructure worldwide that will further enhance our customer service offering."

Alkali operates two large, natural soda ash production facilities – Westvaco and Granger – located in Wyoming, US with a combined production capacity of 4.35 million mtpa:

The combined business of WE Soda and Alkali will be managed as a single operation following an integration process. Over the next five years, WE Soda expects the combined businesses to deliver $1 billion of incremental free cash flow by optimizing growth investment plans while increasing production to around 11 million mtpa.

© Parradee - stock.adobe.com
© Parradee - stock.adobe.com

Company

Logo:

WE Soda Ltd

Head Office 23 College Hill
EC4R 2RP London
UK

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.